|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.320 USD | -2.21% |
|
-11.33% | -39.68% |
| 07-16 | Vanda Reports Positive Opinion for Imsidolimab Orphan Drug Label | MT |
| 07-07 | Vanda Pharmaceuticals Gets FDA Rare Pediatric Disease Designation for CMT2S Therapy | MT |
| Market Cap | 320M 280M 259M 238M 450M 30.85B 457M 3.1B 1.21B 15.09B 1.2B 1.18B 52.01B | P/E 2026 * |
-2.35x | P/E 2027 * | -6.91x |
|---|---|---|---|---|---|
| Enterprise Value | 320M 280M 259M 238M 450M 30.85B 457M 3.1B 1.21B 15.09B 1.2B 1.18B 52.01B | EV / Sales 2026 * |
1.22x | EV / Sales 2027 * | 0.9x |
| Free-Float |
90.02% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Vanda Pharmaceuticals Inc.
| 1 day | -2.21% | ||
| 1 week | -11.33% | ||
| Current month | -13.07% | ||
| 1 month | -8.28% | ||
| 3 months | -23.89% | ||
| 6 months | -31.00% | ||
| Current year | -39.68% |
| 1 week | 5.28 |  | 5.9 |
| 1 month | 5.28 | | 6.62 |
| Current year | 5.28 | | 9.94 |
| 1 year | 4.14 | | 9.94 |
| 3 years | 3.3 | | 9.94 |
| 5 years | 3.3 | | 21.44 |
| 10 years | 3.3 | | 33.44 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 66 | 2003-04-30 | |
Kevin Moran
DFI | Director of Finance/CFO | 42 | 2020-03-14 |
Scott Howell
HRO | Human Resources Officer | 51 | 2019-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 66 | 2021-05-31 | |
Richard Dugan
BRD | Director/Board Member | 84 | 2005-11-30 |
Phaedra Chrousos
BRD | Director/Board Member | 46 | 2019-04-23 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/4/26 | Free | Director | 41,600 | 0.0692% | ||
| 6/4/26 | Free | Director | 41,600 | 0.0692% | ||
| 6/4/26 | Free | Director | 41,600 | 0.0692% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.21% | -11.33% | +11.30% | -16.88% | 327M | |
| +0.21% | -0.79% | +53.17% | +57.39% | 53.83B | |
| +5.37% | +3.31% | +50.39% | +83.65% | 52.1B | |
| -1.20% | -1.94% | +4.35% | +402.68% | 23.48B | |
| +0.74% | +2.32% | -16.23% | -14.44% | 23.13B | |
| -1.05% | -1.15% | +34.86% | -7.22% | 19.36B | |
| -1.18% | -2.97% | +30.12% | -33.30% | 17.56B | |
| -1.67% | -6.00% | +163.95% | +284.69% | 15.2B | |
| -0.95% | +0.08% | +32.04% | +569.26% | 14.83B | |
| -0.70% | -0.91% | +24.87% | +179.47% | 14.06B | |
| Average | -0.30% | -2.57% | +38.88% | +150.53% | 23.39B | |
| Weighted average by Cap. | +0.78% | -1.51% | +41.64% | +133.10% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 262M 230M 212M 195M 368M 25.27B 374M 2.54B 995M 12.36B 984M 962M 42.59B | 357M 313M 289M 266M 501M 34.39B 509M 3.45B 1.35B 16.83B 1.34B 1.31B 57.97B |
| Net income | -135M -119M -110M -101M -190M -13.06B -194M -1.31B -514M -6.39B -509M -498M -22.02B | -54.96M -48.17M -44.52M -40.95M -77.26M -5.3B -78.5M -532M -209M -2.59B -206M -202M -8.93B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-20 | US$5.320 | -2.21% | 1,018,614 |
| 26-07-17 | US$5.440 | -0.18% | 888,721 |
| 26-07-16 | US$5.450 | -6.84% | 1,139,403 |
| 26-07-15 | US$5.850 | 0.00% | 591,576 |
| 26-07-14 | US$5.850 | -2.50% | 1,066,802 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VNDA Stock
Select your edition
All financial news and data tailored to specific country editions
